Skip to search formSkip to main contentSkip to account menu

Bay X 1005

Known as: Bay X1005, BAYX-1005, Bay-X1005 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
FLAP inhibitors for the treatment of inflammatory diseases.
  • A. Sampson
  • Current opinion in investigational drugs
  • 2009
  • Corpus ID: 33308030
Leukotrienes are lipid inflammatory mediators that are implicated in asthma, COPD, arthritis, cardiovascular disease and cancer… 
2007
2007
Leukotriene inhibition in high-risk genotypes
Methods: Investigators conducted a prospective, randomized, placebo-controlled, crossover trial of the leukotriene antagonist (DG… 
Highly Cited
2005
Highly Cited
2005
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
Highly Cited
2005
Highly Cited
2005
The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling…
Background: MMP-13 is one of the most important metalloproteases (MMP) involved in osteoarthritis. Licofelone, a novel dual… 
Highly Cited
2002
Highly Cited
2002
Study of the role of leukotriene B()4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition.
OBJECTIVE To compare the effect of licofelone, NS-398 (an inhibitor of cyclooxygenase 2 [COX-2]), and BayX-1005 (an inhibitor of… 
Review
1997
Review
1997
Biosynthesis inhibitors for leukotrienes in bronchial asthma.
This article reviews the literature on the effects of leukotrienes in asthma. In particular, the ability of recently developed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)